Richard Solomon, MD
Nephrology · Burlington, VTNPI 1619082161
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,928 of the $10,349 with a category attached, or 66.9%. Otsuka America Pharmaceutical, Inc. accounts for 63.1% of it on its own, with 4 other manufacturers making up the rest.
Across 18 payments — averaging $574.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$7K
- Alnylam Pharmaceuticals Inc.$2K
- AstraZeneca$1K
- Bracco Diagnostics Inc.$400
- Otsuka Pharmaceutical Development & Commercialization, Inc.$23
Across 135 payments — averaging $4204.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$234K
- Bayer$122K
- Alnylam Pharmaceuticals Inc.$58K
- Vertex$41K
- Biogen$38K
- CSL Behring$24K
- plus $50K from 4 others
What the payments were for
- Consulting fees$6,92867%
- Travel & lodging$2,97129%
- Food & beverage$4274%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 1 | $6,528 |
| Alnylam Pharmaceuticals Inc. | 4 | $2,042 |
| AstraZeneca | 11 | $1,356 |
| Bracco Diagnostics Inc. | 1 | $400 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few nephrology providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $13,025 |
| Spironolactone | 49 | $727 |
| Mycophenolate Mofetil | 12 | $397 |
| Torsemide | 21 | $334 |
| Furosemide | 15 | $230 |
| Famotidine | 11 | $187 |
| Amlodipine Besylate | 13 | $150 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Burlington
- Macaulay OnuigboBurlington$25K
- Nuria Pastor SolerBurlington$15K
- Kenneth HallowsBurlington$14K
- Abhishek KumarBurlington$509
- Silviana MarineciBurlington$249
- Virginia HoodBurlington$0
- Jeffrey RimmerBurlington$0
- Alison FitzgeraldBurlington$0
- Robert RobeyWhite River Jct$483
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.